Variation in oral calcitriol response in patients with stages 3-4 CKD

Abigail B. Shoben, Gregory Levin, Ian H. De Boer, Catherine Yeung, Suzanne Watnick, Ernie Ayers, Bryan Kestenbaum

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Oral calcitriol decreases parathyroid hormone (PTH) concentrations in patients who have chronic kidney disease (CKD); however, treatment response is highly variable. We evaluated whether patient characteristics affect the PTH response to oral calcitriol in nondialysis patients with CKD in a clinic-based setting. Study Design: Cohort study. Setting & Participants: This study included 379 new oral calcitriol users in the Veterans' Affairs Northwest Health Network. All had stages 3-4 CKD, hyperparathyroidism, and a serum PTH measurement before and 1-6 months after initiating oral calcitriol therapy. Predictors: Patient-level characteristics hypothesized to affect calcitriol response: race, body size, concurrent medications, and kidney function. Outcomes: Relative decrease in serum PTH concentration after starting oral calcitriol therapy. Measurements: Data were abstracted from the Veterans' Affairs Northwest Health Network (VISN 20) Data Warehouse, which includes electronic pharmacy and laboratory records. Results: Mean estimated glomerular filtration rate was 30 mL/min/1.73 m 2 and mean initial PTH concentration was 199 pg/mL. Regular- (0.25 μg/d) and low-dose (

Original languageEnglish (US)
Pages (from-to)645-652
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume59
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Calcitriol
Chronic Renal Insufficiency
Parathyroid Hormone
Veterans
Hyperparathyroidism
Health
Body Size
Serum
Glomerular Filtration Rate
Cohort Studies
Therapeutics
Kidney

Keywords

  • Activated vitamin D
  • calcitriol
  • drug metabolism
  • hyperparathyroidism
  • parathyroid hormone

ASJC Scopus subject areas

  • Nephrology

Cite this

Shoben, A. B., Levin, G., De Boer, I. H., Yeung, C., Watnick, S., Ayers, E., & Kestenbaum, B. (2012). Variation in oral calcitriol response in patients with stages 3-4 CKD. American Journal of Kidney Diseases, 59(5), 645-652. https://doi.org/10.1053/j.ajkd.2011.11.041

Variation in oral calcitriol response in patients with stages 3-4 CKD. / Shoben, Abigail B.; Levin, Gregory; De Boer, Ian H.; Yeung, Catherine; Watnick, Suzanne; Ayers, Ernie; Kestenbaum, Bryan.

In: American Journal of Kidney Diseases, Vol. 59, No. 5, 05.2012, p. 645-652.

Research output: Contribution to journalArticle

Shoben, AB, Levin, G, De Boer, IH, Yeung, C, Watnick, S, Ayers, E & Kestenbaum, B 2012, 'Variation in oral calcitriol response in patients with stages 3-4 CKD', American Journal of Kidney Diseases, vol. 59, no. 5, pp. 645-652. https://doi.org/10.1053/j.ajkd.2011.11.041
Shoben, Abigail B. ; Levin, Gregory ; De Boer, Ian H. ; Yeung, Catherine ; Watnick, Suzanne ; Ayers, Ernie ; Kestenbaum, Bryan. / Variation in oral calcitriol response in patients with stages 3-4 CKD. In: American Journal of Kidney Diseases. 2012 ; Vol. 59, No. 5. pp. 645-652.
@article{aae9ffe53631497e9d47de54b61b3bab,
title = "Variation in oral calcitriol response in patients with stages 3-4 CKD",
abstract = "Background: Oral calcitriol decreases parathyroid hormone (PTH) concentrations in patients who have chronic kidney disease (CKD); however, treatment response is highly variable. We evaluated whether patient characteristics affect the PTH response to oral calcitriol in nondialysis patients with CKD in a clinic-based setting. Study Design: Cohort study. Setting & Participants: This study included 379 new oral calcitriol users in the Veterans' Affairs Northwest Health Network. All had stages 3-4 CKD, hyperparathyroidism, and a serum PTH measurement before and 1-6 months after initiating oral calcitriol therapy. Predictors: Patient-level characteristics hypothesized to affect calcitriol response: race, body size, concurrent medications, and kidney function. Outcomes: Relative decrease in serum PTH concentration after starting oral calcitriol therapy. Measurements: Data were abstracted from the Veterans' Affairs Northwest Health Network (VISN 20) Data Warehouse, which includes electronic pharmacy and laboratory records. Results: Mean estimated glomerular filtration rate was 30 mL/min/1.73 m 2 and mean initial PTH concentration was 199 pg/mL. Regular- (0.25 μg/d) and low-dose (",
keywords = "Activated vitamin D, calcitriol, drug metabolism, hyperparathyroidism, parathyroid hormone",
author = "Shoben, {Abigail B.} and Gregory Levin and {De Boer}, {Ian H.} and Catherine Yeung and Suzanne Watnick and Ernie Ayers and Bryan Kestenbaum",
year = "2012",
month = "5",
doi = "10.1053/j.ajkd.2011.11.041",
language = "English (US)",
volume = "59",
pages = "645--652",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Variation in oral calcitriol response in patients with stages 3-4 CKD

AU - Shoben, Abigail B.

AU - Levin, Gregory

AU - De Boer, Ian H.

AU - Yeung, Catherine

AU - Watnick, Suzanne

AU - Ayers, Ernie

AU - Kestenbaum, Bryan

PY - 2012/5

Y1 - 2012/5

N2 - Background: Oral calcitriol decreases parathyroid hormone (PTH) concentrations in patients who have chronic kidney disease (CKD); however, treatment response is highly variable. We evaluated whether patient characteristics affect the PTH response to oral calcitriol in nondialysis patients with CKD in a clinic-based setting. Study Design: Cohort study. Setting & Participants: This study included 379 new oral calcitriol users in the Veterans' Affairs Northwest Health Network. All had stages 3-4 CKD, hyperparathyroidism, and a serum PTH measurement before and 1-6 months after initiating oral calcitriol therapy. Predictors: Patient-level characteristics hypothesized to affect calcitriol response: race, body size, concurrent medications, and kidney function. Outcomes: Relative decrease in serum PTH concentration after starting oral calcitriol therapy. Measurements: Data were abstracted from the Veterans' Affairs Northwest Health Network (VISN 20) Data Warehouse, which includes electronic pharmacy and laboratory records. Results: Mean estimated glomerular filtration rate was 30 mL/min/1.73 m 2 and mean initial PTH concentration was 199 pg/mL. Regular- (0.25 μg/d) and low-dose (

AB - Background: Oral calcitriol decreases parathyroid hormone (PTH) concentrations in patients who have chronic kidney disease (CKD); however, treatment response is highly variable. We evaluated whether patient characteristics affect the PTH response to oral calcitriol in nondialysis patients with CKD in a clinic-based setting. Study Design: Cohort study. Setting & Participants: This study included 379 new oral calcitriol users in the Veterans' Affairs Northwest Health Network. All had stages 3-4 CKD, hyperparathyroidism, and a serum PTH measurement before and 1-6 months after initiating oral calcitriol therapy. Predictors: Patient-level characteristics hypothesized to affect calcitriol response: race, body size, concurrent medications, and kidney function. Outcomes: Relative decrease in serum PTH concentration after starting oral calcitriol therapy. Measurements: Data were abstracted from the Veterans' Affairs Northwest Health Network (VISN 20) Data Warehouse, which includes electronic pharmacy and laboratory records. Results: Mean estimated glomerular filtration rate was 30 mL/min/1.73 m 2 and mean initial PTH concentration was 199 pg/mL. Regular- (0.25 μg/d) and low-dose (

KW - Activated vitamin D

KW - calcitriol

KW - drug metabolism

KW - hyperparathyroidism

KW - parathyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=84859801372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859801372&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2011.11.041

DO - 10.1053/j.ajkd.2011.11.041

M3 - Article

C2 - 22285224

AN - SCOPUS:84859801372

VL - 59

SP - 645

EP - 652

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 5

ER -